Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsAnna Wade has spoken on 1 earnings call and 2 other investor events across 1 company, most recently for BridgeBio Pharma, Inc. on October 29, 2026. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Charles Homcy (Chairman and Board Member), Brian Stephenson (CFO) and 7 others.
“I'm pleased to say that we continue to have very positive interactions with the agency as they've been conducting their review.”
“So BBP418 is being developed for limb-girdle muscular dystrophy type 2-iron-9. There are no currently approved therapies in the space. And as you said, the OMET need is incredibly high.”
“So, as Tom mentioned, we estimate there are around 2,000 patients in the U.S. with limb girdle musculotistry type 2I. Currently, we have around just over 500 genetically confirmed patients that we currently are tracking, and then we currently have ongoing efforts on patient finding, so that is leveraging the data and…”
Source not stated
Biotechnology · Healthcare
